# Krystal Biotech (KRYS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/KRYS
## Company Profile
- Ticker: KRYS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Gene Therapy, Rare Disease Gene Therapy, Rare Disease
## Stock Data
- Close: 327.05 USD
- Market cap: 8643759256.76 USD
- Last updated: 2026-08-11
## Business Overview
### HSV-1 Gene Therapy Platform
Krystal Biotech develops genetic medicines using modified, non-replicating herpes simplex virus type 1 vectors. The platform supports repeat local administration and is being applied to diseases affecting skin, eye and lung tissue.
### VYJUVEK Franchise
VYJUVEK is a topical gene therapy approved for wounds in dystrophic epidermolysis bullosa. It provides the commercial and regulatory foundation for Krystal’s platform and is being expanded through launches and reimbursement efforts outside the United States.
### KB803 for Corneal Disease
KB803 is being evaluated in the fully enrolled IOLITE registrational study for treatment and prevention of corneal abrasions in patients with dystrophic epidermolysis bullosa. The program applies localized gene delivery to an ocular manifestation of the same genetic disease addressed by VYJUVEK.
### KB801 for Neurotrophic Keratitis
KB801 is in the registrational EMERALD-1 study for neurotrophic keratitis. The candidate uses the company’s designated viral-vector platform and represents a second ophthalmic opportunity.
### Respiratory and Dermatology Pipeline
KB407 is being developed for cystic fibrosis and KB111 for Hailey-Hailey disease. FDA platform technology designation may allow knowledge from shared vector manufacturing and characterization to support these and future programs.
## Why The Stock Is Moving

As of Aug 11, 2026, KRYS closed down 1.37% at $327.05. No new same-company headline was identified in the current news window.

## Future Catalysts

- Dosing initiation in the KB407 cystic-fibrosis program expected in May 2026.
- Topline IOLITE results for KB803 expected in the fourth quarter of 2026.
- Completion of EMERALD-1 enrollment and registrational KB801 data expected by year-end 2026.
- Potential VYJUVEK launches in Italy and Spain in the second half of 2026, subject to reimbursement.

## Recent News
- 2026-08-03 11:00 EST — [Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-second-quarter-2026-financial-and-operating-results-6dbba7e1) — Source: Krystal Biotech
- 2026-07-23 21:00 EST — [Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-report-second-quarter-2026-financial-results-on-august-3-2026-2f96b902) — Source: Krystal Biotech
- 2026-05-18 12:00 EST — [Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa](https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-united-kingdom-mhra-approval-of-vyjuvek-for-the-treatm-23d2eafe) — Source: Krystal Biotech
- 2026-05-07 12:00 EST — [Krystal Biotech to Present at BofA Securities 2026 Health Care Conference](https://biopharmsignal.com/news/KRYS/krystal-biotech-to-present-at-bofa-securities-2026-health-care-conference-f4e6ec6b) — Source: Krystal Biotech
- 2026-05-04 11:00 EST — [Krystal Biotech Announces First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/KRYS/krystal-biotech-announces-first-quarter-2026-financial-and-operating-results-9aa0ae94) — Source: Krystal Biotech